BRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant number of cancers,
including melanoma, thyroid cancer, colorectal cancer and others. Consequently, BRAF inhibitors have been developed as
treatment options for cancers with BRAF mutations which have shown some success in improving patient outcomes in
clinical trials. Development of resistance to BRAF kinase inhibitors is common, however, overcoming this resistance is an
area of significant concern for clinicians, patients and researchers alike. In this review, we identify the mechanisms of
BRAF kinase inhibitor resistance and discuss the implications for strategies to overcome this resistance in the context of
new approaches such as multi-kinase targeted therapies and emerging RNA interference based technologies.